{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:37:09Z","timestamp":1770439029612,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pankind Accelerator Grants"},{"name":"Cancer Institute NSW Translational Program Grant","award":["2020\/TPG2100"],"award-info":[{"award-number":["2020\/TPG2100"]}]},{"name":"Cancer Institute NSW Translational Program Grant","award":["2020\/TPG2100"],"award-info":[{"award-number":["2020\/TPG2100"]}]},{"name":"NHMRC Ideas Grant","award":["APP2002707"],"award-info":[{"award-number":["APP2002707"]}]},{"name":"NHMRC Ideas Grant","award":["APP2002707"],"award-info":[{"award-number":["APP2002707"]}]},{"name":"SPHERE\/Cancer Institute NSW Translational Cancer Research Capacity Building Grant","award":["2021\/CBG0003"],"award-info":[{"award-number":["2021\/CBG0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09411-2","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:20:50Z","timestamp":1751966450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts"],"prefix":"10.1038","volume":"15","author":[{"given":"Shannon","family":"Chiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keilah","family":"Garcia Netto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kokkinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koroush S.","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna S.","family":"Raina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Youkhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omali","family":"Pitiyarachchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quach","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wenholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Laczka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vina R.","family":"Aldilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sharbeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"9411_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"9411_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102427","author":"J Kokkinos","year":"2021","unstructured":"Kokkinos, J. et al. Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer?. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13102427 (2021).","journal-title":"Cancers (Basel)"},{"key":"9411_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184504","author":"S Zeng","year":"2019","unstructured":"Zeng, S. et al. Chemoresistance in pancreatic cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20184504 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"9411_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119742","volume":"240","author":"J Kokkinos","year":"2020","unstructured":"Kokkinos, J. et al. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials 240, 119742. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119742 (2020).","journal-title":"Biomaterials"},{"key":"9411_CR5","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119-6137.e6126. https:\/\/doi.org\/10.1016\/j.cell.2021.11.017 (2021).","journal-title":"Cell"},{"key":"9411_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197307","author":"M Huber","year":"2020","unstructured":"Huber, M. et al. The immune microenvironment in pancreatic cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21197307 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9411_CR7","unstructured":"Phillips, P. Pancreatic Cancer and Tumour Microenvironment (ed Trivandrum) Ch. 3, (Transworld Research Network, 2012)."},{"key":"9411_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00006676-200410000-00002","volume":"29","author":"MV Apte","year":"2004","unstructured":"Apte, M. V. et al. Desmoplastic reaction in pancreatic cancer: Role of pancreatic stellate cells. Pancreas 29, 179\u2013187 (2004).","journal-title":"Pancreas"},{"key":"9411_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fphys.2014.00141","volume":"5","author":"JA McCarroll","year":"2014","unstructured":"McCarroll, J. A. et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front. Physiol. 5, 141. https:\/\/doi.org\/10.3389\/fphys.2014.00141 (2014).","journal-title":"Front. Physiol."},{"key":"9411_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ags3.12225","volume":"3","author":"T Murakami","year":"2019","unstructured":"Murakami, T. et al. Role of the tumor microenvironment in pancreatic cancer. Ann. Gastroenterol. Surg. 3, 130\u2013137. https:\/\/doi.org\/10.1002\/ags3.12225 (2019).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"9411_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.trecan.2019.09.010","volume":"5","author":"BA Pereira","year":"2019","unstructured":"Pereira, B. A. et al. CAF subpopulations: A new reservoir of stromal targets in pancreatic cancer. Trends Cancer 5, 724\u2013741. https:\/\/doi.org\/10.1016\/j.trecan.2019.09.010 (2019).","journal-title":"Trends Cancer"},{"key":"9411_CR12","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1158\/0008-5472.Can-20-2496","volume":"81","author":"G Sharbeen","year":"2021","unstructured":"Sharbeen, G. et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Res. 81, 3461\u20133479. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2496 (2021).","journal-title":"Cancer Res."},{"key":"9411_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413408","author":"U Vaish","year":"2021","unstructured":"Vaish, U., Jain, T., Are, A. C. & Dudeja, V. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: An update on heterogeneity and therapeutic targeting. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms222413408 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"9411_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/path.5926","volume":"257","author":"S Menezes","year":"2022","unstructured":"Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M. & Cameron, A. J. M. Cancer-associated fibroblasts in pancreatic cancer: New subtypes, new markers, new targets. J. Pathol. 257, 526\u2013544. https:\/\/doi.org\/10.1002\/path.5926 (2022).","journal-title":"J. Pathol."},{"key":"9411_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo, R., Xavier, C. P. R., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: Molecular and clinical perspectives. Trends Mol. Med. 29, 439\u2013453. https:\/\/doi.org\/10.1016\/j.molmed.2023.03.002 (2023).","journal-title":"Trends Mol. Med."},{"key":"9411_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596. https:\/\/doi.org\/10.1084\/jem.20162024 (2017).","journal-title":"J. Exp. Med."},{"key":"9411_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.Cd-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0710 (2019).","journal-title":"Cancer Discov."},{"key":"9411_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.Cd-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0094 (2019).","journal-title":"Cancer Discov."},{"key":"9411_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655152","volume":"9","author":"X Geng","year":"2021","unstructured":"Geng, X. et al. Cancer-Associated Fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front. Cell Dev. Biol. 9, 655152. https:\/\/doi.org\/10.3389\/fcell.2021.655152 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"9411_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1242\/dmm.021055","volume":"8","author":"A Gopinathan","year":"2015","unstructured":"Gopinathan, A., Morton, J. P., Jodrell, D. I. & Sansom, O. J. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis. Model Mech. 8, 1185\u20131200. https:\/\/doi.org\/10.1242\/dmm.021055 (2015).","journal-title":"Dis. Model Mech."},{"key":"9411_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13402-021-00585-1","volume":"44","author":"A Bengtsson","year":"2021","unstructured":"Bengtsson, A. et al. Organoid technology for personalized pancreatic cancer therapy. Cell Oncol. (Dordr.) 44, 251\u2013260. https:\/\/doi.org\/10.1007\/s13402-021-00585-1 (2021).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"9411_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338. https:\/\/doi.org\/10.1016\/j.cell.2014.12.021 (2015).","journal-title":"Cell"},{"key":"9411_CR23","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","volume":"116","author":"E Driehuis","year":"2019","unstructured":"Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl. Acad. Sci. U. S. A. 116, 26580\u201326590. https:\/\/doi.org\/10.1073\/pnas.1911273116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"9411_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102750","author":"PO Frappart","year":"2020","unstructured":"Frappart, P. O. & Hofmann, T. G. Pancreatic Ductal Adenocarcinoma (PDAC) organoids: The shining light at the end of the tunnel for drug response prediction and personalized medicine. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12102750 (2020).","journal-title":"Cancers (Basel)"},{"key":"9411_CR25","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41598-021-81299-0","volume":"11","author":"J Kokkinos","year":"2021","unstructured":"Kokkinos, J. et al. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci. Rep. 11, 1944. https:\/\/doi.org\/10.1038\/s41598-021-81299-0 (2021).","journal-title":"Sci. Rep."},{"key":"9411_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102711","volume":"4","author":"AR Decker-Farrell","year":"2023","unstructured":"Decker-Farrell, A. R., Ma, A., Li, F., Muir, A. & Olive, K. P. Generation and ex vivo culture of murine and human pancreatic ductal adenocarcinoma tissue slice explants. STAR Protoc. 4, 102711. https:\/\/doi.org\/10.1016\/j.xpro.2023.102711 (2023).","journal-title":"STAR Protoc."},{"key":"9411_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00280-016-3224-2","volume":"79","author":"MW Saif","year":"2017","unstructured":"Saif, M. W., Heaton, A., Lilischkis, K., Garner, J. & Brown, D. M. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). Cancer Chemother. Pharmacol. 79, 303\u2013314. https:\/\/doi.org\/10.1007\/s00280-016-3224-2 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"9411_CR28","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1038\/s41598-018-22882-w","volume":"8","author":"AJ Stevenson","year":"2018","unstructured":"Stevenson, A. J. et al. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Sci. Rep. 8, 5144. https:\/\/doi.org\/10.1038\/s41598-018-22882-w (2018).","journal-title":"Sci. Rep."},{"key":"9411_CR29","doi-asserted-by":"publisher","first-page":"10909","DOI":"10.3390\/app122110909","volume":"12","author":"J Ceramella","year":"2022","unstructured":"Ceramella, J. et al. A look at the importance of chirality in drug activity: Some significative examples. Appl. Sci. 12, 10909 (2022).","journal-title":"Appl. Sci."},{"key":"9411_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-017-0448-5","volume":"10","author":"D von Ahrens","year":"2017","unstructured":"von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A. & Verma, A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. Hematol. Oncol. 10, 76. https:\/\/doi.org\/10.1186\/s13045-017-0448-5 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"9411_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/chir.23559","volume":"35","author":"P Behera","year":"2023","unstructured":"Behera, P., Ramakrishna, D. S., Chandrasekhar, M. M. & Kothakapu, S. R. A concise review on recent advances in catalytic asymmetric hydrogenation. Chirality 35, 477\u2013497. https:\/\/doi.org\/10.1002\/chir.23559 (2023).","journal-title":"Chirality"},{"key":"9411_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S. & Letellier, E. In search of definitions: Cancer-associated fibroblasts and their markers. Int. J. Cancer 146, 895\u2013905. https:\/\/doi.org\/10.1002\/ijc.32193 (2020).","journal-title":"Int. J. Cancer"},{"key":"9411_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005 (2014).","journal-title":"Cancer Cell"},{"key":"9411_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735\u2013747. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.021 (2014).","journal-title":"Cancer Cell"},{"key":"9411_CR35","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1158\/1078-0432.Ccr-20-3715","volume":"27","author":"NG Steele","year":"2021","unstructured":"Steele, N. G. et al. Inhibition of Hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin. Cancer Res. 27, 2023\u20132037. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3715 (2021).","journal-title":"Clin. Cancer Res."},{"key":"9411_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110227","volume":"38","author":"ER Murray","year":"2022","unstructured":"Murray, E. R. et al. Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell. Rep. 38, 110227. https:\/\/doi.org\/10.1016\/j.celrep.2021.110227 (2022).","journal-title":"Cell. Rep."},{"key":"9411_CR37","doi-asserted-by":"publisher","first-page":"6571674","DOI":"10.1155\/2020\/6571674","volume":"2020","author":"MS Kim","year":"2020","unstructured":"Kim, M. S. et al. Cucurbitacin D induces G2\/M phase arrest and apoptosis via the ROS\/p38 pathway in Capan-1 pancreatic cancer cell line. Evid. Based Complement Alternat. Med. 2020, 6571674. https:\/\/doi.org\/10.1155\/2020\/6571674 (2020).","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"9411_CR38","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar, S. et al. Targeting pancreatic cancer by TAK-981: A SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut 71, 2266\u20132283. https:\/\/doi.org\/10.1136\/gutjnl-2021-324834 (2022).","journal-title":"Gut"},{"key":"9411_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1091\/mbc.E11-09-0781","volume":"23","author":"JD Orth","year":"2012","unstructured":"Orth, J. D., Loewer, A., Lahav, G. & Mitchison, T. J. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol. Biol. Cell 23, 567\u2013576. https:\/\/doi.org\/10.1091\/mbc.E11-09-0781 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"9411_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1158\/1535-7163.Mct-16-0005","volume":"15","author":"AB Alvero","year":"2016","unstructured":"Alvero, A. B. et al. TRX-E-002-1 induces c-jun-dependent apoptosis in ovarian cancer stem cells and prevents recurrence in vivo. Mol. Cancer Ther. 15, 1279\u20131290. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0005 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"9411_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020416","author":"F Di Costanzo","year":"2023","unstructured":"Di Costanzo, F., Di Costanzo, F., Antonuzzo, L., Mazza, E. & Giommoni, E. Optimizing first-line chemotherapy in metastatic pancreatic cancer: Efficacy of FOLFIRINOX versus nab-paclitaxel plus gemcitabine. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15020416 (2023).","journal-title":"Cancers (Basel)"},{"key":"9411_CR42","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson, H. M., Chandana, S., Wright, G. P. & Chung, M. Pancreatic cancer: A review of current treatment and novel therapies. J. Invest. Surg. 36, 2129884. https:\/\/doi.org\/10.1080\/08941939.2022.2129884 (2023).","journal-title":"J. Invest. Surg."},{"key":"9411_CR43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.Can-07-2477","volume":"68","author":"A Vonlaufen","year":"2008","unstructured":"Vonlaufen, A. et al. Pancreatic stellate cells: Partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085\u20132093. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-2477 (2008).","journal-title":"Cancer Res."},{"key":"9411_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell 181, 424-441.e421. https:\/\/doi.org\/10.1016\/j.cell.2020.03.008 (2020).","journal-title":"Cell"},{"key":"9411_CR45","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1038\/s41467-019-10968-6","volume":"10","author":"C Vennin","year":"2019","unstructured":"Vennin, C. et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat. Commun. 10, 3637. https:\/\/doi.org\/10.1038\/s41467-019-10968-6 (2019).","journal-title":"Nat. Commun."},{"key":"9411_CR46","doi-asserted-by":"publisher","first-page":"16887","DOI":"10.1038\/s41598-017-17177-5","volume":"7","author":"JRW Conway","year":"2017","unstructured":"Conway, J. R. W. et al. Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology. Sci. Rep. 7, 16887. https:\/\/doi.org\/10.1038\/s41598-017-17177-5 (2017).","journal-title":"Sci. Rep."},{"key":"9411_CR47","doi-asserted-by":"publisher","first-page":"9216","DOI":"10.18632\/oncotarget.13985","volume":"8","author":"G Sharbeen","year":"2017","unstructured":"Sharbeen, G. et al. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget 8, 9216\u20139229. https:\/\/doi.org\/10.18632\/oncotarget.13985 (2017).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09411-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:20:54Z","timestamp":1751966454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09411-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9411"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09411-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As part of an industry partnership research contract with UNSW, Noxopharm provided the novel compounds to the Pancreatic Cancer Translational Research Group at UNSW led by P.A. Phillips. The therapeutic assessment of these compounds was conducted independently by the group, and the results were reported to Noxopharm as stipulated in the contract. In addition, Quach Truong, Daniel Wenholz, John Wilkinson, Olivier Laczka, and Xiang Li are paid employes of Noxopharm. All other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study is reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"ARRIVE statement"}},{"value":"N. Kumar (patents: US20080306140, US20040152761)) synthesized the series of novel chromans, CRO-05, CRO-67, and CRO-68, in collaboration with Noxopharm Limited, and report a composition of matter patent for WO2023235929. As part of an industry partnership research contract with UNSW, Noxopharm provided the novel compounds to the Pancreatic Cancer Translational Research Group at UNSW led by P.A. Phillips. The therapeutic assessment of these compounds was conducted independently by the group, and the results were reported to Noxopharm as stipulated in the contract. No disclosures were reported by the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors disclosures"}}],"article-number":"24488"}}